0.46
-0.0066(-1.42%)
Currency In USD
| Previous Close | 0.46 |
| Open | 0.47 |
| Day High | 0.59 |
| Day Low | 0.44 |
| 52-Week High | 3.85 |
| 52-Week Low | 0.4 |
| Volume | 2.2M |
| Average Volume | 1.59M |
| Market Cap | 4.86M |
| PE | -0.13 |
| EPS | -3.5 |
| Moving Average 50 Days | 0.68 |
| Moving Average 200 Days | 1.38 |
| Change | -0.01 |
If you invested $1000 in GT Biopharma, Inc. (GTBP) since IPO date, it would be worth $0.54 as of February 17, 2026 at a share price of $0.457. Whereas If you bought $1000 worth of GT Biopharma, Inc. (GTBP) shares 5 years ago, it would be worth $2.37 as of February 17, 2026 at a share price of $0.457.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
GlobeNewswire Inc.
8 hours ago
SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
GlobeNewswire Inc.
Feb 03, 2026 1:30 PM GMT
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to ex
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
GlobeNewswire Inc.
Jan 15, 2026 1:30 PM GMT
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cash runway into Q3 2026 SAN FRANCISCO, CALIFORNIA, J